Skip to main content

Articles

Page 1 of 1

  1. abc

    Authors: Beatriz Moreno, Gemma Vila, Begoña Fernandez-Diez, Raquel Vázquez, Alessandra di Penta, Oihana Errea, Nagore Escala, Andrés Miguez, Jordi Alberch and Pablo Villoslada
    Citation: Multiple Sclerosis and Demyelinating Disorders 2019 4:3

    The original article was published in Multiple Sclerosis and Demyelinating Disorders 2017 2:3

  2. Currently, there are few established pharmacogenetic predictors of response to treatment in multiple sclerosis (MS) patients. Commonly used second line treatments include natalizumab that has proven to be succ...

    Authors: Malak Al-Mojel, Raed Alroughani, Texy Kannankeril, Mohammed Dashti and Rabeah Al-Temaimi
    Citation: Multiple Sclerosis and Demyelinating Disorders 2019 4:2
  3. In comparison to non-minority patients with multiple sclerosis, minority research in multiple sclerosis continues to be only a few percent of the literature. Often, the comparator group is with the Caucasian p...

    Authors: Diamond Garcia, Jason Ledesma, Kristen Berube, Sarah Valdez, Eric Tamrazian and Bijal Mehta
    Citation: Multiple Sclerosis and Demyelinating Disorders 2019 4:1
  4. The scenario of multiple sclerosis (MS) treatment has changed profoundly in recent decades. In this setting, one of two strategies is usually used: escalation or induction. The first involves a pyramid of poss...

    Authors: Serena Ruggieri, Simona Pontecorvo, Carla Tortorella and Claudio Gasperini
    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:5
  5. There are few reports about the actual state of diagnosis for multiple sclerosis (MS) in Japan. In addition, in late years multiple disease-modifying drugs (DMDs) were released in Japan, but there are few repo...

    Authors: Katsutoshi Hiramatsu, Masakazu Hase and Hirofumi Ochi
    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:4
  6. Treatment algorithms for neuromyelitis optica spectrum disorder (NMOSD) vary, and sparse data exist regarding the impact of initial treatments on disease course. We aimed to determine whether administration of...

    Authors: Sabrina Gmuca, Rui Xiao, Pamela F. Weiss, Amy T. Waldman and Jeffrey S. Gerber
    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:3
  7. Multiple sclerosis (MS) is increasingly recognized in the paediatric age. In a smaller, but well-established, proportion of paediatric MS patients [20% of total paediatric MS cases: 0.2% to 0.7% of the total MS p...

    Authors: Vincenzo Salpietro, Agata Polizzi, Gaia Recca and Martino Ruggieri
    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:2
  8. Progressive brain atrophy is a major feature of multiple sclerosis (MS) pathology and is actually considered a major determinant of the progressive accumulation of physical and cognitive disability in MS patie...

    Authors: Alice Favaretto, Andrea Lazzarotto, Monica Margoni, Davide Poggiali and Paolo Gallo
    Citation: Multiple Sclerosis and Demyelinating Disorders 2018 3:1
  9. First recognized at the beginning of twentieth century and named after three authors who independently described some affected patients, Vogt-Koyanagi-Harada syndrome is a rare multisystemic autoimmune disease...

    Authors: Marta Scarioni, Anna M. Pietroboni, Alessandro Invernizzi, Francesco Viola, Laura Ghezzi, Alberto Calvi, Tiziana Carandini, Milena De Riz, Daniela Galimberti and Elio Scarpini
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:14
  10. Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with a very high economic impact. Peginterferon beta-1a is the first approved pegylated interferon beta-1a for the treatm...

    Authors: Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani and Pier Luigi Canonico
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:13
  11. To assess the association between objective bladder function parameters in relation to urinary symptoms, and to analyze the sensitivity and specificity of subjective urinary symptom-assessment in predicting ob...

    Authors: Shalom Haggiag, Giovanni Bolla, Orietta Picconi, Simonetta Galgani and Claudio Gasperini
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:11
  12. Mitoxantrone (MX) has been used as second line therapy for aggressive multiple sclerosis (MS). Potential cardiotoxic effects of MX limit its use; a cumulative dose of up to 100 mg/m2, has been long considered ...

    Authors: Paolo Ragonese, Paolo Aridon, Sabrina Realmuto, Giulia Vazzoler, Simona Alessi, Erika Portera, Alessia Bianchi, Fabio Triolo, Maria Antonietta Mazzola, Marco D’Amelio, Giovanni Savettieri and Giuseppe Salemi
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:12
  13. We prospectively assessed the influence of JCV- status on disability’s accrual in RRMS patients treated with Natalizumab at two tertiary MS centres, settled in Italy.

    Authors: E. D’Amico, A. Zanghì, A. Signori, LME Grimaldi and F. Patti
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:9
  14. Fingolimod is an efficacious treatment for relapsing-remitting multiple sclerosis (RRMS) and there is class I evidence that it is superior to standard care in reducing relapse rate. However, real-world data in...

    Authors: Manuela Giuliani, Alessandra Logoteta, Luca Prosperini, Maria Neve Hirsch and Carlo Pozzilli
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:10
  15. Cognitive dysfunction is frequent in multiple sclerosis patients and has important and negative consequences for daily activities and quality of life of subjects. Disease modifying treatments for multiple scle...

    Authors: Claudia Niccolai, Benedetta Goretti and Maria Pia Amato
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:8
  16. Alemtuzumab (Lemtrada®) is a humanized anti-CD52 IgG1 monoclonal antibody that depletes CD52-expressing cells from the circulation. Robust clinical and radiologic data, derived from clinical trials and long-te...

    Authors: Paolo Gallo, Diego Centonze and Maria Giovanna Marrosu
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:7
  17. In this review the most important aspects of pediatric multiple sclerosis are presented and compared with the adult form. Some findings appear peculiar of pediatric MS:

    a.
     

    Authors: Angelo Ghezzi, Damiano Baroncini, Mauro Zaffaroni and Giancarlo Comi
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:5
  18. Along with vitamin D, smoking, body mass index and others, Epstein Barr virus, other herpesviruses and human endogenous retroviruses represent plausible environmental risk factors for multiple sclerosis. Howev...

    Authors: M. C. Buscarinu, A. Fornasiero, S. Romano, M. Ferraldeschi, R. Renié, G. Trasimeni, M. Salvetti and G. Ristori
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:6
  19. Methylthioadenosine is a metabolite of the polyamine pathway that modulates methyltransferase activity, thereby influencing DNA and protein methylation. Since methylthioadenosine produces neuroprotection in mo...

    Authors: Beatriz Moreno, Gemma Vila, Begoña Fernandez-Diez, Raquel Vázquez, Alessandra di Penta, Oihana Errea, Nagore Escala, Andrés Miguez, Jordi Alberch and Pablo Villoslada
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:3

    The Correction to this article has been published in Multiple Sclerosis and Demyelinating Disorders 2019 4:3

  20. Despite intense research, the causes of various neurological diseases remain enigmatic to date. A role for viral or bacterial infection and associated molecular mimicry has frequently been suggested in the eti...

    Authors: Jussi Tuusa, Arne Raasakka, Salla Ruskamo and Petri Kursula
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:4
  21. Cognitive impairment is very frequent during multiple sclerosis (MS), involving approximately 40–70% of the patients, with a profound impact on patient’s life. It is now established that among the various cent...

    Authors: Andrea Mancini, Lorenzo Gaetani, Maria Di Gregorio, Alessandro Tozzi, Veronica Ghiglieri, Paolo Calabresi and Massimiliano Di Filippo
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:2
  22. Despite cognitive deficits frequently represent the first clinical manifestations of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated MS patients, the importance of cognitive deficits in...

    Authors: Cristina Scarpazza, Nicola De Rossi, Lucia Moiola, Simonetta Gerevini, Mirco Cosottini, Ruggero Capra and Flavia Mattioli
    Citation: Multiple Sclerosis and Demyelinating Disorders 2017 2:1
  23. The immunopathogenesis of pediatric multiple sclerosis (MS) is not well understood.

    Authors: Vikram Bhise, Konstantin Balashov, Marc Sturgill, Lauren Krupp and Suhayl Dhib-Jalbut
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:15
  24. Immediately following immunoablation and hematopoietic stem cell transplantation (IA-HSCT) for MS a median decrease in brain volume of 3.2 % over 2.4 months occurs. After 2 years, rates of atrophy are comparab...

    Authors: Lisa A. S. Walker, Jason A. Berard, Marjorie Bowman, Harold L. Atkins, Hyunwoo Lee, Douglas Arnold and Mark S. Freedman
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:12
  25. Alemtuzumab is a monoclonal antibody, which was recently approved for the treatment of active relapsing remitting multiple sclerosis. Its main mechanism of action is based on targeting CD52, an antigen of unkn...

    Authors: Lina Hassoun, Judith Eisele, Katja Thomas and Tjalf Ziemssen
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:10
  26. Natalizumab is highly effective in reducing multiple sclerosis disease activity; however it carries a risk of progressive multifocal leukoencephalopathy, that represents the main reason of drug discontinuation...

    Authors: Simona Malucchi, Marco Capobianco, Alessia di Sapio, Marianna Lo Re, Paola Cavalla and Antonio Bertolotto
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:11
  27. Progressive multiple sclerosis (MS) is characterized clinically by the accumulation of neurological disability without unequivocal recovery. Understanding the mechanisms that determine entering in this stage o...

    Authors: Fernando Pérez-Cerdá, María Victoria Sánchez-Gómez and Carlos Matute
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:9
  28. Multiple sclerosis (MS) is a chronic and progressively debilitating disease of the central nervous system. Treatment of MS involves disease-modifying therapies (DMTs) to reduce the incidence of relapses and pr...

    Authors: Giancarlo Comi, Maria Pia Amato, Antonio Bertolotto, Diego Centonze, Nicola De Stefano, Cinthia Farina, Paolo Gallo, Angelo Ghezzi, Luigi Maria Grimaldi, Gianluigi Mancardi, Maria Giovanna Marrosu, Enrico Montanari, Francesco Patti, Carlo Pozzilli, Leandro Provinciali, Marco Salvetti…
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:6
  29. We aim to identify differentially expressed genes (DEGs) and its pathways associated with clinical activity of relapsing–remitting Multiple Sclerosis (RRMS).

    Authors: Ion Agirrezabal, Ricardo Palacios, Beatriz Moreno, Jorge Sepulcre, Alice Abernathy, Albert Saiz, Sara Llufriu, Manuel Comabella, Xavier Montalban, Antonio Martinez, David Arteta and Pablo Villoslada
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:7
  30. The discovery that several demyelinating disorders in children may be associated with autoantibodies to astrocytes, myelin, and/or synaptic proteins has opened the possibility of their use as diagnostic and pr...

    Authors: Thaís Armangue, Anusha K. Yeshokumar, Maria Sepúlveda, Francesc Graus and Albert Saiz
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:5
  31. Dysfunction of higher cognitive abilities occurs in 40–60 % of people with multiple sclerosis (MS), as detected with neuropsychological testing, with predominant involvement of executive functions and processi...

    Authors: N. Amato, M. Cursi, M. Rodegher, L. Moiola, B. Colombo, M. Falautano, F. Possa, G. Comi, V. Martinelli and L. Leocani
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:8
  32. Fingolimod is approved by EMA as a second-line treatment for relapsing-remitting multiple sclerosis (RRMS). Experience with fingolimod in real life is still limited. Aim of our study was to report data on fing...

    Authors: D. Baroncini, M. Zaffaroni, P. O. Annovazzi, S. Baldini, A. Bianchi, G. Minonzio, G. Comi and A. Ghezzi
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:4
  33. The most suitable setting of rehabilitation for Persons with Multiple Sclerosis (PwMS) has not been identified so far because there is a general lacking of controlled studies. Aim of this study was to evaluate...

    Authors: Angelo Pappalardo, Emanuele D’Amico, Carmela Leone, Silvia Messina, Clara Chisari, L. Rampello, Lina Torre and Francesco Patti
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:3
  34. The increasing amount of highly effective treatment options in relapsing forms of multiple sclerosis (MS) requires innovative clinical trial design strategies. These strategies may encompass the application of...

    Authors: Manolo E. Beelke, Paola Antonini and Michael F. Murphy
    Citation: Multiple Sclerosis and Demyelinating Disorders 2016 1:2